| Literature DB >> 29997176 |
Subhalakshmi Sharma1, Kateřina Čermáková2,3,4,5, Jan De Rijck6, Jonas Demeulemeester1, Milan Fábry7, Sara El Ashkar1, Siska Van Belle1, Martin Lepšík2, Petr Tesina2,7, Vojtěch Duchoslav2, Petr Novák8, Martin Hubálek2, Pavel Srb2, Frauke Christ1, Pavlína Řezáčová2,7, H Courtney Hodges3,4,5,9, Zeger Debyser6, Václav Veverka10,11.
Abstract
Lens epithelium-derived growth factor/p75 (LEDGF/p75, or PSIP1) is a transcriptional coactivator that tethers other proteins to gene bodies. The chromatin tethering function of LEDGF/p75 is hijacked by HIV integrase to ensure viral integration at sites of active transcription. LEDGF/p75 is also important for the development of mixed-lineage leukemia (MLL), where it tethers the MLL1 fusion complex at aberrant MLL targets, inducing malignant transformation. However, little is known about how the LEDGF/p75 protein interaction network is regulated. Here, we obtained solution structures of the complete interfaces between the LEDGF/p75 integrase binding domain (IBD) and its cellular binding partners and validated another binding partner, Mediator subunit 1 (MED1). We reveal that structurally conserved IBD-binding motifs (IBMs) on known LEDGF/p75 binding partners can be regulated by phosphorylation, permitting switching between low- and high-affinity states. Finally, we show that elimination of IBM phosphorylation sites on MLL1 disrupts the oncogenic potential of primary MLL1-rearranged leukemic cells. Our results demonstrate that kinase-dependent phosphorylation of MLL1 represents a previously unknown oncogenic dependency that may be harnessed in the treatment of MLL-rearranged leukemia.Entities:
Keywords: LEDGF/p75; disordered proteins; leukemia; phosphorylation; protein–protein interactions
Mesh:
Substances:
Year: 2018 PMID: 29997176 PMCID: PMC6065015 DOI: 10.1073/pnas.1803909115
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205